Ashwagandha for Sleep: A Systematic Evidence Review

Does ashwagandha improve sleep outcomes in adults?

9 studies 872 participants 2019–2026

Evidence supports: Sleep Quality, Sleep Onset Latency, Total Sleep Time, Sleep Maintenance +1 more

Early data: Sleep Efficiency, Daytime Sleepiness

Abstract

Ashwagandha likely improves sleep in adults, and the clearest benefit is better overall sleep quality.¹²³⁴⁵⁶⁷⁸⁹ Across 8 trials, the average effect was large on paper, but the lived change looks more modest on validated sleep scales: about a 1.8-point improvement on the Pittsburgh Sleep Quality Index, a 21-point scale where 3 points is usually considered a clearly meaningful change (pooled d 1.13, 95% CI 0.70 to 1.55; NNT 4.8, meaning about 1 in 5 people achieve a clearly meaningful benefit).¹⁴⁷⁸⁹ That makes the result worth taking seriously, but not a promise of dramatic sleep transformation.

Ashwagandha also shows encouraging signs for the mechanics of sleep itself, especially falling asleep faster.¹ In the best direct actigraphy trial, people taking 600 mg/day fell asleep about 5 minutes faster than placebo and showed better sleep efficiency, reaching 83.5% versus 79.7%.¹ Total sleep time rose by about 19 minutes and wake after sleep onset fell by about 7 minutes, but those specific differences did not reach statistical significance in that study.¹ These are promising signals, yet they still rest mostly on one overnight measurement study, so replication matters.

Daytime effects are weaker than nighttime effects.¹³ Morning alertness appears to improve slightly, but the change is probably subtle rather than dramatic (pooled d 0.50, 95% CI 0.08 to 0.91).¹³ Daytime sleepiness, by contrast, has not been directly tested in the current analysis, so claims that ashwagandha makes people less sleepy during the day are not yet supported.

The main limitation is variability. Sleep quality results differed a lot across studies (I-squared 84.6%, a measure of between-study disagreement), and the prediction interval crossed no effect, meaning some future study settings could plausibly show little or no benefit even if the average result remains positive.¹²³⁴⁵⁶⁷⁸⁹

In Plain Language

Ashwagandha probably helps sleep, mostly by making sleep feel better overall rather than by dramatically changing every part of the night. The best-supported benefit is better sleep quality. It may also help you fall asleep a little faster and sleep a bit more smoothly, but those results need more confirmation. If you are hoping to feel much less sleepy during the day, the current research does not answer that well.

One plain recommendation: if stress and restless sleep tend to show up together for you, ashwagandha is a reasonable supplement to try, but expect a modest improvement, not a knockout effect.

Introduction

The question is simple: does ashwagandha actually help adults sleep better, or does it mainly improve stress and leave sleep as a side story? The current analysis points to a real sleep signal, with the strongest support for better overall sleep quality and thinner but still encouraging evidence for faster sleep onset and smoother nighttime sleep.¹²³⁴⁵⁶⁷⁸⁹

That distinction matters because “better sleep” can mean different things. A supplement might improve how sleep feels without changing objective overnight measures, or it might shorten the time needed to fall asleep without improving next-day function. The evidence reviewed here suggests ashwagandha does best on broad sleep-quality outcomes, especially in stressed adults and in one insomnia trial, while the case for changes in total sleep time, sleep maintenance, and daytime functioning is less fully mapped.¹³⁴⁵⁷⁸⁹

The practical answer is cautiously favorable. Ashwagandha appears more likely to make sleep feel somewhat better than to produce a dramatic overhaul of every sleep dimension. That is still meaningful, especially when sleep problems travel with stress, but it sets realistic expectations from the start.¹²⁴⁵⁷⁸⁹

Evidence 1 of 3

Better sleep is the main story

Ashwagandha likely improves overall sleep quality, and this is the most convincing finding in the review.¹²³⁴⁵⁶⁷⁸⁹ Across 8 trials and 12 sleep-quality endpoints, the pooled effect favored ashwagandha clearly (pooled d 1.13, 95% CI 0.70 to 1.55).¹²³⁴⁵⁶⁷⁸⁹ That effect looks large statistically, but the more grounded estimate is the native-unit change: about a 1.8-point drop on the PSQI, a 21-point scale where 3 points is usually considered the threshold for a clearly meaningful improvement.¹⁴⁷⁸⁹ So the average person is more likely to notice somewhat better sleep than to experience a complete reset.

The consistency of direction matters more than the exact size, and nearly every study points the same way.¹²³⁴⁵⁶⁷⁸⁹ In adults with insomnia, 600 mg/day lowered PSQI from the placebo-group level of 11.84 to 9.15 after 10 weeks, still not perfect sleep but clearly improved.¹ In stressed but otherwise healthy adults, sustained-release 300 mg/day brought PSQI down to 2.5 versus 4.0 after 90 days, and another 12-week trial reported a mean PSQI improvement of 2.6 points versus 0.7 with placebo.⁴⁷ A 60-day trial using a full-spectrum extract found that 53.6% achieved at least a 3-point PSQI improvement, compared with 24.6% on placebo, which works out to about 1 extra clear responder for every 5 people treated.⁸

The effect is credible, but not equally reliable in every setting.¹²³⁴⁵⁶⁷⁸⁹ Heterogeneity was high (I-squared 84.6%), meaning study results varied more than chance alone would explain, and the prediction interval ranged from essentially no effect to a very large one (-0.01 to 2.31).¹²³⁴⁵⁶⁷⁸⁹ That usually means the average benefit is real, but factors like population, extract type, baseline stress, and outcome scale probably influence how much benefit shows up in a given trial. The evidence reviewed here is therefore strong enough to support “likely helps,” but not precise enough to say everyone should expect the same degree of improvement.

What this means

Expect a meaningful chance of sleeping better overall, but usually by a modest amount rather than a dramatic one. Ashwagandha seems most useful for improving how sleep feels across the night as a whole, especially in people who are stressed or already sleeping poorly.¹⁴⁷⁸

Sleep Quality

Likely helps Strong · 74

8 studies N=1,525 d_RE=1.13 (0.70 to 1.55) p=<.001 NNT=4.8 I²=85%

Likely modest benefit

K 2021 (n=130)

0.83

E 2026 (n=113)

0.28

S 2026 (n=85)

0.95

M 2025 (n=90)

0.49

O 2025 (n=30)

2.58

D 2019 (n=58)

1.19

J 2019 (n=39)

1.55

S 2020 (n=39)

2.01

Pooled

1.13

Favours control MCID Favours supplement

▸ GRADE Assessment

Domain	Rating	Reason
Risk of bias	No concern	11 papers, majority low risk
Inconsistency	Serious	I²=85% (> 75%)
Imprecision	No concern	N=1525 meets OIS=400
Publication bias	No concern	Egger's p=0.638, no asymmetry detected (k=10)
Indirectness	No concern	deferred to Phase 2 (#1546)
Overall certainty	Moderate

Evidence 2 of 3

Nighttime sleep mechanics show promise, but the evidence is thin

Ashwagandha suggests real benefits for the mechanics of sleep, especially falling asleep faster, but this part of the case is still built mostly on one actigraphy trial.¹ In adults with primary insomnia taking 600 mg/day for 10 weeks, sleep onset latency fell to 29.0 minutes versus 34.0 minutes with placebo, a roughly 5-minute advantage that meets commonly used thresholds for a noticeable benefit (d 0.53).¹ That is not the kind of change that turns severe insomnia into effortless sleep, but it is enough to matter for someone who regularly lies awake waiting to drift off.

Ashwagandha also appears to make sleep more consolidated once it starts.¹ In the same trial, sleep efficiency, which is the percentage of time in bed actually spent asleep, rose to 83.5% versus 79.7% with placebo (d 0.68).¹ A few percentage points can be felt as less tossing and turning and fewer long stretches awake in bed. Wake after sleep onset also moved in the right direction, 33.1 versus 40.0 minutes, a roughly 7-minute difference that looks clinically relevant by insomnia-trial standards even though that single comparison was not statistically significant in the published study (d 0.39).¹

The gain in total sleep time looks smaller and less secure than the gain in sleep continuity.¹ The same trial found about 19 extra minutes of sleep, 311.6 versus 292.4 minutes, but that falls short of the usual 30-minute threshold used to define a clearly meaningful improvement and did not reach statistical significance (d 0.45, p=0.076).¹ That pattern matters: ashwagandha may be better at smoothing sleep and shortening the path into sleep than at substantially extending the night.

The promising part of this story should not be mistaken for settled evidence.¹ These outcomes have moderate or low certainty mostly because they rely on just one contributing study in this dataset, with total sample size below the usual information threshold and limited ability to judge publication bias or subgroup effects. The current analysis therefore supports nighttime benefits as plausible and encouraging, not as fully established across formulations and populations.

What this means

If ashwagandha helps, the most likely changes are falling asleep a bit sooner and spending a bit more of the night actually asleep. Sleeping much longer is possible, but not yet convincingly shown.¹

Sleep Onset Latency

Likely helps Strong · 70

1 study N=339 NNT=6.3

Likely strong benefit

Single study: D 2019, d=0.66 (n=39+19)

▸ GRADE Assessment

Domain	Rating	Reason
Risk of bias	No concern	2 papers, majority low risk
Inconsistency	No concern	no concerns (I²=0%, consistency=100%)
Imprecision	Serious	N=339 below OIS=400
Publication bias	No concern	k=2 usable (< 10), cannot assess per Cochrane 10.4
Indirectness	No concern	deferred to Phase 2 (#1546)
Overall certainty	Moderate

Total Sleep Time

Likely helps Strong · 70

1 study N=339

Likely modest benefit

Single study: D 2019, d=0.48 (n=39+19)

▸ GRADE Assessment

Domain	Rating	Reason
Risk of bias	No concern	2 papers, majority low risk
Inconsistency	No concern	no concerns (I²=0%, consistency=100%)
Imprecision	Serious	N=339 below OIS=400
Publication bias	No concern	k=2 usable (< 10), cannot assess per Cochrane 10.4
Indirectness	No concern	deferred to Phase 2 (#1546)
Overall certainty	Moderate

Sleep Efficiency

Early data Limited · 45

1 study N=339

Promising early signal

Single study: D 2019, d=1.16 (n=39+19)

▸ GRADE Assessment

Domain	Rating	Reason
Risk of bias	No concern	2 papers, majority low risk
Inconsistency	Serious	I²=55% (> 50%)
Imprecision	Serious	N=339 below OIS=400
Publication bias	No concern	k=2 usable (< 10), cannot assess per Cochrane 10.4
Indirectness	No concern	deferred to Phase 2 (#1546)
Overall certainty	Low

Sleep Maintenance

Likely helps Strong · 70

1 study N=339 NNT=10.3

Likely strong benefit

Single study: D 2019, d=0.51 (n=39+19)

▸ GRADE Assessment

Domain	Rating	Reason
Risk of bias	No concern	2 papers, majority low risk
Inconsistency	No concern	no concerns (I²=0%, consistency=100%)
Imprecision	Serious	N=339 below OIS=400
Publication bias	No concern	k=2 usable (< 10), cannot assess per Cochrane 10.4
Indirectness	No concern	deferred to Phase 2 (#1546)
Overall certainty	Moderate

Evidence 3 of 3

Daytime carryover is modest and partly unmeasured

Morning alertness likely improves slightly, but the change is probably subtle for most people.¹³ Pooling the available studies gave a small positive effect (pooled d 0.50, 95% CI 0.08 to 0.91), and the studies were statistically consistent with each other (I-squared 0%), meaning they pointed in the same direction.¹³ In an elderly sample, the 3-point morning alertness score improved from 1.35 to 1.05 after 12 weeks, where lower meant feeling more alert on rising.³ In the insomnia trial, 69.2% rated themselves as alert on waking versus 52.6% on placebo, but that difference was not statistically significant.¹

The size of the alertness gain matters here, because statistical significance can overstate lived importance.¹³ The pooled effect is positive, but its clinical importance looks trivial overall. That means some people may notice a cleaner start to the morning, while many others may not feel much difference beyond the nighttime improvements themselves.

Daytime sleepiness remains an evidence gap in the current analysis.³ One study reported a sleepiness scale in older adults, but the reporting was too incomplete to support a dependable pooled estimate, and there are no direct analyzed daytime-sleepiness endpoints across the review dataset. As a result, the current analysis does not support claims that ashwagandha reliably reduces feeling sleepy during the day. Better sleep at night does not automatically guarantee better daytime functioning, and that distinction still needs to be tested more directly.

What this means

Morning function may improve a little, but daytime benefits are much less certain than nighttime ones. The current evidence is not enough to say ashwagandha reliably makes people less sleepy during the day.¹³

Daytime Sleepiness

Not enough research Very early · 35

0 studies N=0

Not enough research

▸ GRADE Assessment

Domain	Rating	Reason
Risk of bias	Serious	1/1 papers with RoB concerns
Inconsistency	No concern	single study, inconsistency N/A
Imprecision	Serious	sample size unknown
Publication bias	No concern	no d values
Indirectness	No concern	deferred to Phase 2 (#1546)
Overall certainty	Low

Next-Day Alertness and Sleep-Related Daytime Function

Likely helps Strong · 67

2 studies N=267 d_RE=0.50 (0.08 to 0.91) p=0.021 I²=0%

Likely modest benefit

S 2020 (n=39)

0.66

D 2019 (n=58)

0.37

Pooled

0.50

Favours control MCID Favours supplement

▸ GRADE Assessment

Domain	Rating	Reason
Risk of bias	No concern	3 papers, majority low risk
Inconsistency	No concern	no concerns (I²=0%, consistency=100%, PI crosses null)
Imprecision	Serious	N=267 below OIS=400
Publication bias	No concern	k=3 usable (< 10), cannot assess per Cochrane 10.4
Indirectness	No concern	deferred to Phase 2 (#1546)
Overall certainty	Moderate

Across the Evidence

The clearest pattern is that ashwagandha helps broad sleep quality more consistently than any single sleep mechanic.¹²³⁴⁵⁶⁷⁸⁹ That makes biological and methodological sense. Many of these trials enrolled stressed adults, and ashwagandha is usually studied as an adaptogen, so improvements in stress reactivity may show up first as “I’m sleeping better overall” before they show up as large shifts in every actigraphy variable. Broad scales like the PSQI also capture multiple domains at once, including latency, disturbances, and restorative quality, which makes them more likely to register a meaningful overall change than a single overnight metric.

Objective and subjective findings generally point in the same direction, which strengthens the overall story, but the objective side is still too thin to carry the case by itself.¹ The actigraphy trial improved sleep onset latency and sleep efficiency and moved total sleep time and wake-after-sleep-onset in the same favorable direction.¹ That agreement is reassuring because it suggests the sleep-quality signal is not purely expectancy or questionnaire noise. Still, one well-done overnight study is not the same thing as a replicated objective evidence base.

Some of the largest standardized effects should be interpreted cautiously because scale choice can inflate apparent magnitude.²³⁶ A change of 1 to 2 points on a 7-point sleep rating can produce a very large standardized effect if variability is small, even when the lived difference is closer to “noticeably better” than “transformative.” The PSQI results help anchor expectations better: average improvement is in the modest but tangible range, not a wholesale normalization of sleep for most people.¹⁴⁷⁸⁹

The weaker daytime signal also fits the broader pattern.¹³ If ashwagandha primarily reduces hyperarousal or stress-related sleep disruption, the first gains should appear at night. Morning alertness may then improve a little as a downstream effect, but daytime sleepiness depends on many other things, including sleep duration, circadian timing, workload, and baseline fatigue. Since daytime sleepiness was not directly studied here, the current analysis is more convincing about nights than days.

The evidence does not yet support confident claims about dose-response or formulation superiority.¹²³⁴⁵⁷⁸⁹ Benefits appear across 125 mg to 700 mg daily, with KSM-66, Sensoril, sustained-release preparations, and other standardized extracts all showing positive sleep-quality results in at least some settings.¹²⁴⁵⁷⁸⁹ But the studies differ too much in population, scale, and duration to say that one extract clearly outperforms another or that higher doses consistently work better.

Discussion

The overall conclusion is favorable but bounded: ashwagandha likely improves sleep, mainly by making overall sleep quality better, with thinner evidence that it also helps people fall asleep faster and sleep more efficiently.¹²³⁴⁵⁶⁷⁸⁹ The confidence is strongest for the broad sleep-quality outcome because that finding is replicated across multiple randomized trials and multiple formulations. The confidence is lower for the more granular sleep mechanics because those results lean heavily on a single actigraphy study.¹

What is supported is fairly specific. The current analysis supports better self-rated sleep quality, a modest chance of achieving a clearly meaningful PSQI improvement, and a small possible gain in morning alertness.¹³⁴⁷⁸⁹ What is not yet supported is a confident claim that ashwagandha meaningfully lengthens sleep for most people, consistently improves every component of sleep architecture, or reliably reduces daytime sleepiness.¹³

The main reason not to overstate the case is variability, not absence of effect.¹²³⁴⁵⁶⁷⁸⁹ High heterogeneity in sleep quality means the average benefit is convincing, but the expected size of benefit is not uniform across settings. Some of that likely reflects real differences in baseline sleep problems, stress burden, study populations, and outcome scales. Some may also reflect ordinary supplement-trial issues, including small samples, short follow-up, per-protocol analyses in several studies, and industry-linked products in part of the literature.²³⁶⁸⁹

What would change confidence most is straightforward: more objective sleep studies, more direct comparisons between extract types and doses, and trials that measure next-day functioning as carefully as nighttime sleep. Until then, the evidence reviewed here supports ashwagandha as a reasonable option for modest sleep improvement, especially when stress and poor sleep travel together, but not as a universally potent sleep solution.

Methodology

We searched PubMed for studies on ashwagandha and sleep, then filtered the results to human randomized controlled trials that matched the review question. Nine studies were included from a larger PubMed corpus, covering 872 participants across 2019-2026.¹²³⁴⁵⁶⁷⁸⁹

We read each study and recorded what it measured, how large it was, how long it lasted, and what it found. We assessed evidence quality with the GRADE framework and judged clinical importance against published meaningful-change thresholds, such as the 3-point threshold on the PSQI. Every study cited here is publicly indexed on PubMed and can be checked directly.

GRADE is useful, but it was built mainly for pharmaceutical interventions and often rates nutrition and supplement evidence conservatively. It automatically downgrades observational research and usually upgrades only for very large effects, so supplement evidence can end up labeled “low certainty” even when multiple randomized trials point in the same practical direction. Our trust score adds a continuous estimate of how believable and clinically meaningful the finding is, calibrated to whether the change is likely to be noticeable in real life. When those two views diverge, the prose reflects both: cautious about trial limitations, but not blind to consistent, tangible benefit.

Known limitations include short study durations, small samples in several trials, inconsistent outcome measures, incomplete daytime-function assessment, and industry links in part of the literature.²³⁶⁸⁹

Study Selection

98 Papers in ashwagandha corpus

2 wrong study type

11 With matching outcomes

9 After study type & comparator filters

9 Included in review

Characteristics of Included Studies

Study	Design	N	Population	Dose	Duration	RoB
D 2019 FT	rct	60	clinical	600 mg daily (300 mg twice daily) for 10 weeks	10 weeks	Some
J 2019 FT	rct	60	healthy	250 mg/day (125 mg twice daily) for 8 weeks	8 weeks	Some
S 2020 FT	rct	50	healthy	600 mg daily (300 mg twice daily) for 12 weeks	12 weeks	Some
K 2021 FT	rct	130	healthy	300 mg once daily for 90 days	90 days	Low
S 2024 FT	rct	131	subclinical	1250000 00 mg daily for 8 weeks	8 weeks	Some
O 2025 FT	rct	30	healthy	600 mg daily for 28 days	28 days	Some
M 2025 FT	rct	90	clinical	125 mg daily for 12 weeks	84 days (plus 7-day screening)	Some
E 2026 FT	rct	186	subclinical	700 mg daily (350 mg capsule ×2 daily) for 60 days	60 days	Some
S 2026 FT	rct	135	healthy	150 mg daily for 60 days	60 days	Some

Sources